Oral tolerance and inflammatory bowel disease

Current Opinion in Gastroenterology

Volumn 21, Issue 6, 2005, Pages 692-696

  Kraus, Thomas A ^a   Mayer, Lloyd ^b,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c Immunobiology Center   (United States)

Author keywords

Crohn's disease; Inflammatory bowel disease; Oral tolerance

Indexed keywords

ANTIGEN; GLYCOPROTEIN; GLYCOPROTEIN GP 180; KEYHOLE LIMPET HEMOCYANIN; UNCLASSIFIED DRUG;

CROHN DISEASE; DENDRITIC CELL; ENTERITIS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; NONHUMAN; ORAL TOLERANCE; REVIEW; SUPPRESSOR CELL; T LYMPHOCYTE;

ANIMALS; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; IMMUNE TOLERANCE; IMMUNITY, MUCOSAL; IMMUNOTHERAPY; MOUTH MUCOSA;

EID: 27644506101     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mog.0000182862.88798.28     Document Type: Review

References (53)

1. Knoflach P, Park BH, Cunningham R, et al. Serum antibodies to cow's milk proteins in ulcerative colitis and Crohn's disease. Gastroenterology 1987; 92:479-485.
2. Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 102:448-455.
3. Duchmann R, May E, Heike M, et al. T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans. Gut 1999; 44:812-818.
4. Duchmann R, Schmitt E, Knolle P, et al. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol 1996; 26:934-938.
5. H2 development.
6. Mayer L, Eisenhardt D. Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease. J Clin Invest 1990; 86:1255-1260.
7. Toy LS, Yio XY, Lin A, et al. Defective expression of gp180, a novel CD8 ligand on intestinal epithelial cells, in inflammatory bowel disease. J Clin Invest 1997; 100:2062-2071.
8. Ferguson A, Ziegler K, Strobel S. Gluten intolerance (coeliac disease). Ann Allergy 1984; 53:637-642.
9. Duchmann R, Neurath MF, Meyer zum Buschenfelde KH. Responses to self and non-self intestinal microflora in health and inflammatory bowel disease. Res Immunol 1997; 148:589-594.
10. Friedman A, Weiner H. Induction of anergy or active suppression following oral tolerance is determined by antigen dose. Proc Natl Acad Sci USA 1994; 91:6688.
11. Fukaura H, Kent SC, Pietrusewicz MJ, et al. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor beta-1 secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest 1996; 98:70-77.
12. Groux H, O'Garra A, Bigler M, et al. A CD4+ T cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389:737-742.
13. Chen Y, Inobe J, Marks R, et al. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 1995; 376:177-180.
14. Garside P, Steel M, Liew FY, Mowat AM. CD4+ but not CD8+ T cells are required for the induction of oral tolerance. Int Immunol 1995; 7:501-504.
15. Challacombe SJ, Tomasi TB. Systemic tolerance and secretory immunity after oral immunization. J Exp Med 1980; 152:1459-1472.
16. Mowat AM, Ferguson A. Migration inhibition of lymph node lymphocytes as an assay for regional cell-mediated immunity in the intestinal lymphoid tissues of mice immunized orally with ovalbumin. Immunology 1982; 47:365-370.
17. Lider O, Santos LM, Lee CS, et al. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. II. Suppression of disease and in vitro immune responses is mediated by antigen-specific CD8+ T lymphocytes. J Immunol 1989; 142:748-752.
18. Thomas HC, Parrot MV. The induction of tolerance to a soluble protein by oral administration. Immunology 1974; 27:631-639.
19. Allez M, Brimnes J, Dotan I, Mayer L. Expansion of CD8+ T cells with regulatory function after interaction with intestinal epithelial cells. Gastroenterology 2002; 123:1516-1526.
20. Brimnes J, Allez M, Dotan I, et al. Defects in CD8+ regulatory T cells in the lamina propria of patients with inflammatory bowel disease. J Immunol 2005; 174:5814-5822.
21. Viney JL, Mowat AM, O'Malley JM, et al. Expanding dendritic cells in vivo enhances the induction of oral tolerance. J Immunol 1998; 160:5815-5825.
22. Rescigno M, Urbano M, Valzasina B, et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2001; 2:361-367.
23. Macpherson AJ, Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science 2004; 303:1662-1665. This work shows that mucosal dendritic cells help set up the protective IgA response to commensal bacteria while limiting them to the mucosal immune system.
24. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411:603-606.
25. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411:599-603.
26. Inohara N, Ogura Y, Fontalba A, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2: implications for Crohn's disease. J Biol Chem 2003; 278:5509-5512.
27. Inohara N, Nunez G. NODs: intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol 2003; 3:371-382.
28. Girardin SE, Boneca IG, Viala J, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003; 278:8869-8872.
29. Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005; 307:731-734. This work demonstrates that Nod-2 deficient mice are susceptible to bacterial infections through the oral route and that Nod-2 is required for the expression of cryptdins.
30. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000; 68:7010-7017.
31. Singh JC, Cruickshank SM, Newton DJ, et al. Toll-like receptor-mediated responses of primary intestinal epithelial cells during the development of colitis. Am J Physiol Gastrointest Liver Physiol 2005; 288:G514-G524.
32. Cario E. Bacterial interactions with cells of the intestinal mucosa: toll-like receptors and NOD2. Gut 2005; 54:1182-1193. This excellent review covers the known pathogen recognition molecules of the gut and their relation to human disease.
33. Nagler-Anderson C, Bober LA, Robinson ME, et al. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci USA 1986; 83:7443-7446.
34. Higgins PJ, Weiner HL. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J Immunol 1988; 140:440-445.
35. Myers LK, Pihlajamaa T, Brand DD, et al. Immunogenicity of recombinant type IX collagen in murine collagen-induced arthritis. Arthritis Rheum 2002; 46:1086-1093.
36. Cobelens PM, Kavelaars A, Vroon A, et al. The beta 2-adrenergic agonist salbutamol potentiates oral induction of tolerance, suppressing adjuvant arthritis and antigen-specific immunity. J Immunol 2002; 169:5028-5035.
37. Zavazava N, Fandrich F, Zhu X, et al. Oral feeding of an immunodominant MHC donor-derived synthetic class I peptide prolongs graft survival of heterotopic cardiac allografts in a high-responder rat strain combination. J Leukoc Biol 2000; 67:793-800.
38. Stepkowski SM, Yu J, Wang M, Kahan BD. Induction of tolerance by oral administration of a tolerogenic allochimeric donor/recipient class I MHC protein. Transplant Proc 1999; 31:1557.
39. Vrabec TR, Gregerson DS, Dua HS, Donoso LA. Inhibition of experimental autoimmune uveoretinitis by oral administration of S-antigen and synthetic peptides. Autoimmunity 1992; 12:175-184.
40. Bergerot I, Ploix C, Petersen J, et al. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci USA 1997; 94:4610-4614.
41. Ilan Y, Weksler-Zangen S, Ben-Horin S, et al. Treatment of experimental colitis by oral tolerance induction: a central role for suppressor lymphocytes. Am J Gastroenterol 2000; 95:966-973.
42. Neurath MF, Fuss I, Kelsall BL, et al. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med 1996; 183:2605-2616.
43. Neurath M, Fuss I, Strober W. TNBS-colitis. Int Rev Immunol 2000; 19:51-62.
44. Bouma G, Kaushiva A, Strober W. Experimental murine colitis is regulated by two genetic loci, including one on chromosome 11 that regulates IL-12 responses. Gastroenterology 2002; 123:554-565.
45. Weiner HL, Mackin GA, Matsui M, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993; 259:1321-324.
46. Trentham DE, Dynesius-Trentham RA, Orav EJ, et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993; 261:1727-1730.
47. Husby S, Mestecky J, Moldoveanu Z, et al. Oral tolerance in humans: T cell but not B cell tolerance after antigen feeding. J Immunol 1994; 152:4663-4670.
48. Campbell NA, Kim HS, Blumberg RS, Mayer L. The nonclassical class I molecule CD1d associates with the novel CD8 ligand gp180 on intestinal epithelial cells. J Biol Chem 1999; 274:26259-26265.
49. Campbell NA, Park MS, Toy LS, et al. A non-class I MHC intestinal epithelial surface glycoprotein, gp180, binds to CD8. Clin Immunol 2002; 102:267-274.
50. Kraus TA, Toy L, Chan L, et al. Failure to induce oral tolerance to a soluble protein in patients with inflammatory bowel disease. Gastroenterology 2004; 126:1771-1778. This oral tolerance study in patients with Crohn's disease and ulcerative colitis indicates that IBD patients are defective in their ability to tolerize to a fed neoantigen.
51. Binder V, Orholm M. Familial occurrence and inheritance studies in inflammatory bowel disease. Neth J Med 1996; 48:53-56.
52. Kraus TA, Toy L, Chan L, et al. Failure to induce oral tolerance in Crohn's and ulcerative colitis patients: possible genetic risk. Ann N Y Acad Sci 2004; 1029:225-238.
53. Ilan Y. Oral immune regulation toward disease-associated antigens: results of phase I clinical trials in Crohn's disease and chronic hepatitis. Ann N Y Acad Sci 2004; 1029:286-298. This is the only oral tolerance trial for IBD. The results are more favorable than those of oral tolerance trails for other diseases to date.